Borderline Resectable Pancreatic Ductal Adenocarcinoma Clinical Trials

6 recruiting

Borderline Resectable Pancreatic Ductal Adenocarcinoma Trials at a Glance

6 actively recruiting trials for borderline resectable pancreatic ductal adenocarcinoma are listed on ClinicalTrialsFinder across 5 cities in 3 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Atlanta, Buffalo, and Portland. Lead sponsors running borderline resectable pancreatic ductal adenocarcinoma studies include Emory University, British Columbia Cancer Agency, and OHSU Knight Cancer Institute.

Browse borderline resectable pancreatic ductal adenocarcinoma trials by phase

Treatments under study

About Borderline Resectable Pancreatic Ductal Adenocarcinoma Clinical Trials

Looking for clinical trials for Borderline Resectable Pancreatic Ductal Adenocarcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Borderline Resectable Pancreatic Ductal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Borderline Resectable Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Resectable Pancreatic Adenocarcinoma+2 more
Emory University36 enrolled1 locationNCT06423326
Recruiting
Phase 2

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

Borderline Resectable Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute20 enrolled1 locationNCT06821997
Recruiting
Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Not Applicable

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
British Columbia Cancer Agency200 enrolled1 locationNCT06574620
Recruiting
Phase 2

PULSAR in Systemic Therapy for Pancreatic Cancer

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaOligometastatic Pancreatic Ductal Adenocarcinoma
Samsung Medical Center47 enrolled1 locationNCT07269626
Recruiting

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy

Borderline Resectable Pancreatic Ductal AdenocarcinomaStage I Pancreatic Cancer AJCC v8Resectable Pancreatic Ductal Adenocarcinoma
Emory University87 enrolled1 locationNCT06595160